2 results
Approved WMOCompleted
Part 1: To assess the safety and effectiveness of subcutaneous golimumab 50 mg (SC-GLM50), administered by autoinjection once monthly during 6 months, when combined with different DMARD regimens used in daily rheumatology. Part 2: In subjects who…
Approved WMOPending
1)To determine whether subjects at ultra high risk to develop schizophrenia display hepatic insulin resistance as compared to healthy controls matched for age, sex, BMI, ethnicity, visceral and subcutaneous fat mass.2)To determine whether…